MTOR and chromophobe renal cell carcinoma: In the KEYNOTE-B61 trial, ORR was 28% for the chRCC subgroup (n = 29); again, the chRCC subgroup responded poorly relative to the pRCC subgroup (33).The enhanced anticancer activity of lenvatinib plus everolimus and lenvatinib plus pembrolizumab relative to sunitinib and pembrolizumab alone in the chRCC subgroup supports the hypothesis that dual inhibition of the VEGFR and mTOR pathways is a preferred therapeutic strategy for this histology.